Evidence map›Paper›PMID 25209104›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2015

Angiotensin AT2 receptor stimulation is anti-inflammatory in lipopolysaccharide-activated THP-1 macrophages via increased interleukin-10 production.

Isha Dhande, Wanshu Ma, Tahir Hussain

Open access · bronzeAbstract read
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 83 citations in OpenAlex.

  1. Review
  2. ERK1/2 activation in anti-inflammatory effects and underlying signaling mechanisms.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Elucidating the complex interplay between chronic kidney disease and hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Macrophage angiotensin ATAmerican journal of physiology. Renal physiology · 2023
    Article
  11. Article
  12. Review
  13. COVID-19 and Diarylamidines: The Parasitic Connection.International journal of molecular sciences · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Angiotensin ATFrontiers in immunology · 2022
    Article
  19. Observational
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Isha Dhande1] Department of Pharmacological and Pharmaceutical Sciences, Heart and Kidney Institute, University of Houston, Houston, TX, USA [2] Department of Pharmacal Sciences, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.
Wanshu MaDepartment of Pharmacal Sciences, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.
Tahir Hussain1] Department of Pharmacological and Pharmaceutical Sciences, Heart and Kidney Institute, University of Houston, Houston, TX, USA [2] Department of Pharmacal Sciences, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.
Auburn University · USUniversity of Houston · US

Funding

Renal Angiotensin ll Receptor Function in ObesityR01DK061578 · NIDDK · UNIVERSITY OF HOUSTON · PI HUSSAIN, TAHIR · 2003 to 2020
$4.3M
NIDDK NIH HHS R01 DK061578NIDDK NIH HHS R01 DK-61578
6 · The paper itself

Abstract

Macrophages have an important role in the pathogenesis of hypertension and associated end-organ damage via the activation of the Toll-like receptors, such as Toll-like receptor-4 (TLR4). Accumulating evidence suggests that the angiotensin AT2 receptor (AT2R) has a protective role in pathological conditions involving inflammation and tissue injury. We have recently shown that AT(2)R stimulation is renoprotective, which occurs in part via increased levels of anti-inflammatory interleukin-10 (IL-10) production in renal epithelial cells; however, the role of AT(2)R in the inflammatory activity of macrophages is not known. The present study was designed to investigate whether AT(2)R activation stimulates an anti-inflammatory response in TLR4-induced inflammation. The effects of the anti-inflammatory mechanisms that occurred following pre-treatment with the AT(2)R agonist Compound 21 (C21) (1 μmol ml(-1)) on the cytokine profiles of THP-1 macrophages after activation by lipopolysaccharide (LPS) (1 μg ml(-1)) were studied. The AT(2)R agonist dose-dependently attenuated LPS-induced tumor necrosis factor-α (TNF-α) and IL-6 production but increased IL-10 production. IL-10 was critical for the anti-inflammatory effects of AT(2)R stimulation because the IL-10-neutralizing antibody dose-dependently abolished the AT(2)R-mediated decrease in TNF-α levels. Further, enhanced IL-10 levels were associated with a sustained, selective increase in the phosphorylation of extracellular signal-regulated kinase (ERK1/2) but not p38 mitogen-activated protein kinase (MAPK). Blocking the activation of ERK1/2 before C21 pre-treatment completely abrogated this increased IL-10 production in response to the AT(2)R agonist C21, while there was a partial reduction in IL-10 levels following the inhibition of p38. We conclude that AT(2)R stimulation exerts a novel anti-inflammatory response in THP-1 macrophages via enhanced IL-10 production as a result of sustained, selective ERK1/2 phosphorylation, which may have protective roles in hypertension and associated tissue injury.

Indexed as

Anti-Inflammatory AgentsBenzimidazolesBiphenyl CompoundsCell LineDrug Evaluation, PreclinicalExtracellular Signal-Regulated MAP KinasesHumansInflammationInterleukin-10LipopolysaccharidesMacrophagesp38 Mitogen-Activated Protein KinasesReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2TetrazolesAnti-Inflammatory AgentsBenzimidazolesBiphenyl CompoundscandesartanExtracellular Signal-Regulated MAP KinasesIL10 protein, humanInterleukin-10Lipopolysaccharidesp38 Mitogen-Activated Protein KinasesReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Tetrazoles

Identifiers

PMID25209104
PMCPMC4898267
OpenAlexW2007000106

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.